All research
Semaglutide 2023-04-01 ClinicalTrials

Retatrutide, a Triple Agonist, Explored for Kidney Parameter Modulation in Type 2 Diabetes

Obesity Treatment to Improve Diabetes

Abstract

Retatrutide, a GIP/GLP-1/glucagon receptor agonist, was assessed for its impact on kidney parameters in patients with type 2 diabetes mellitus (T2D) and kidney disease.


Source: clinicaltrials:NCT05390307 · Ingested 2026-06-04 · Digest: gemini-2.5-flash